Lung Cancer | Leora Horn, MD, MSc and Yanjun Ma, MD

published 2 weeks ago by Dr Neil Love

Visiting Professors: Lung Cancer Edition — Part 2: Our discussion with Drs Horn and Ma highlights the following topics as well as cases from Dr Ma’s practice: Case: A woman in her mid-70s with Stage IV lung adenocarcinoma and a PD-L1 TPS of 70% experiences a pathologic fracture of the right femur while receiving first-line pembrolizumab (00:00) Pembrolizumab monotherapy versus carboplatin/pemetrexed/pembrolizumab as first-line therapy for patients with metastatic NSCLC and a high TPS (02:30) Radiation necrosis as a potential cause of pathologic fractures (05:18) Thyroid dysfunction and pancreatitis associated with pembrolizumab (08:12) Case: A man in his early 50s with metastatic lung cancer of ambiguous histology experiences a dramatic response to first-line nab paclitaxel/carboplatin (11:11) Utility of liquid biopsies in therapeutic decision-making for patients with metastatic lung cancer (13:03) Therapy for patients with metastatic lung cancer and CNS metastases (15:11) Therapeutic approach for patients with metastatic lung cancer of undetermined histology (20:30) Second-line therapy for patients with metastatic lung cancer (22:41) Case: A woman in her mid-80s with metastatic lung adenocarcinoma and a PD-L1 TPS of 30% receives pemetrexed/pembrolizumab and experiences dyspnea (28:14) Perspective on the approach to metastatic lung adenocarcinoma in elderly patients (30:52) Efficacy of ramucirumab as second-line therapy for patients with metastatic NSCLC (36:24) REVEL: Results of a Phase III trial evaluating the addition of ramucirumab to docetaxel after disease progression on platinum-based therapy for patients with Stage IV NSCLC (37:44) Comparison of the activity and tolerability of ramucirumab to that of bevacizumab in patients with metastatic squamous cell carcinoma of the lung (40:11) Ongoing clinical investigation of novel combination approaches with immune checkpoint inhibitors and anti-angiogenic agents (41:49) Case: A man in his mid-70s, a former smoker, with Stage III NSCLC initially treated with adjuvant chemoradiation therapy develops metastatic disease and is found to have a RET tumor mutation (43:40) Effects of tumor mutation burden and PD-L1 expression on response to immune checkpoint inhibitors (47:32) Perspective on the use of targeted therapy as first-line treatment for patients with metastatic NSCLC (49:32) Sequencing targeted therapy and immune checkpoint inhibitors for patients with metastatic NSCLC and actionable tumor mutations (51:08) Case: A woman in her early 60s with lung adenocarcinoma and oligometastatic disease in the brain receives first-line chemoradiation therapy (56:39) Cardiomyopathy associated with checkpoint inhibitor therapy (1:00:08) Prolonged responses to anti-PD-1/PD-L1 antibodies after cessation of therapy (1:03:27) PD-L1 expression as a predictor of response to immune checkpoint inhibitors (1:07:40) Case: A man in his early 70s with metastatic NSCLC develops a severe carboplatin-related allergy during treatment with carboplatin/nab paclitaxel/pembrolizumab (1:09:41) Benefits of early palliative care in the management of metastatic NSCLC (1:15:22) CME information and select publications  

more episodes from Research To Practice | Oncology Videos